Sharemaestro Newsreel

Parallel Advisors LLC Purchases New Position in Astrazeneca Plc $AZN

Parallel Advisors LLC has acquired a new position in AstraZeneca Plc, purchasing 8,718 shares valued at approximately $1.72 million in the first quarter. This comes as institutional investors collectively own 20.35% of AstraZeneca, and analysts maintain a "Moderate Buy" consensus rating with an average …

161,624 Shares in Astrazeneca Plc $AZN Acquired by Professional Advisory Services Inc.

Professional Advisory Services Inc. recently acquired 161,624 shares of AstraZeneca Plc (NYSE:AZN) for approximately $30.2 million, making it their seventh-largest holding. AstraZeneca reported strong quarterly earnings, beating EPS estimates, and analysts maintain a "Moderate Buy" rating for the stock. The company's financial performance and …

Should Gilead’s Swing to a Full‑Year Loss Outlook Require Action From Gilead Sciences (GILD) Investors?

Gilead Sciences recently reported a significant net loss of US$10.50 billion in Q2 2026, alongside cutting its full-year earnings outlook despite higher revenue. This shift to a projected full-year loss raises questions about how the company will balance investment, capital returns, and future financing, …

Glaxosmithkline plc - ADR (GSK) News, Articles, Events & Latest Updates

This article provides recent news and updates concerning Glaxosmithkline plc (GSK), alongside other pharmaceutical companies. Key highlights include GSK beating Q2 earnings and revenue estimates and announcing a cost-saving plan, as well as news about Moderna's mRNA flu vaccine approval and other companies' financial …

Assenagon Asset Management S.A. Has $69.25 Million Position in Amgen Inc. $AMGN

Assenagon Asset Management S.A. significantly reduced its stake in Amgen Inc. by 44.5% during the second quarter, now holding 191,247 shares valued at $69.25 million. Despite this, other institutional investors have increased their positions, and analysts have set new price targets, with a consensus …

Novo Nordisk makes Omnicom agency of record for US media buying

Novo Nordisk has appointed Omnicom as its agency of record for U.S. media buying, ending its six-year partnership with WPP's Wavemaker. The agreement, valued at $520 million, will see Omnicom manage Novo's media buying in the U.S. starting in the fourth quarter. This move …

Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)

AstraZeneca PLC Stock 12‑Month Price Target Raised to $216.47, Implies 34% Upside

AstraZeneca PLC's average 12-month price target has been increased to $216.47, up from $215.03, according to 26 analysts. This updated target suggests a potential upside of approximately 34% based on the August 6 closing price. The consensus rating from 31 analysts remains a "Buy," …

Healthcare giant slashes key consultation fee to beat rivals

CVS Health (CVS) is targeting the earliest point in a customer's weight-loss drug decision: the first consultation. On Aug. 5, the company dropped the cash price of a MinuteClinic online weight-loss visit to $29, with no membership and no monthly fee. That is the …

St. Louis Financial Planners Asset Management LLC Takes $5.01 Million Position in AbbVie Inc. $ABBV

St. Louis Financial Planners Asset Management LLC has acquired a new position in AbbVie Inc., purchasing 19,202 shares valued at approximately $5.01 million, making AbbVie its seventh-largest holding. This comes as AbbVie reported strong Q2 earnings, exceeding revenue and EPS expectations, though its adjusted …

Organon & Co. $OGN Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly reduced its stake in Organon & Co. ($OGN) by 3.5% in the first quarter, selling over 118,000 shares while still retaining a substantial holding. Despite this reduction and a consensus "Reduce" rating from analysts with an average price target …

3rd Circ. Says Pharma Co. Suit Against Merck Belongs In India

The Third Circuit has ruled that a legal dispute between pharmaceutical giant Merck and a now-defunct Indian pharmaceutical company must be litigated in India. The case revolves around a terminated business relationship between the two entities. This decision establishes the proper jurisdiction for the …

Ebola response turns to Merck vaccine, Gilead drug as Congo outbreak worsens

The Ebola response in eastern Democratic Republic of Congo is intensifying, with plans to expand the use of Merck & Co.'s Ebola vaccine, Ervebo, and Gilead Sciences Inc.'s antiviral drug, remdesivir. This comes as the current Bundibugyo strain outbreak, which has caused nearly 4,000 …

Amarin (AMRN) Q2 2026 Earnings Call Transcript

Amgen SVP & CCO Nancy Grygiel disposes of $1.19m in stock

Amgen's SVP & CCO, Nancy A. Grygiel, sold approximately $1.19 million worth of Amgen stock on August 6, 2026. This transaction was related to the exercise of non-qualified stock options, with the sales primarily covering the exercise price and withholding taxes. Following these transactions, …

Merck & Co. Insider Sold Shares Worth $6,805,145, According to a Recent SEC Filing

A recent SEC filing revealed that Caroline L. Sweeney, an insider at Merck & Co. (NYSE:MRK), sold 54,775 shares of the company's stock for a total value of $6,805,145. This transaction occurred on August 6, 2026, with shares sold at an average price of …

Price to earnings forward of Medicus Pharma Ltd. – NASDAQ:MDCX

The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?

Quick Read A blended portfolio made up of two-thirds dividend growth at 3.5% and one-third income at 6% generates $56,000 annually from $1.25M, beating the 4% rule without touching principal. Dividend growers like JNJ and AMGN raising payouts at 6% annually double retirement income …

Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem

Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from …

Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells 52,847 Shares of Stock

Merck & Co., Inc. EVP David Michael Williams sold 52,847 shares of company stock for approximately $6.81 million, significantly reducing his direct ownership. The company reported strong quarterly results, exceeding revenue and EPS estimates, and declared an $0.85 quarterly dividend. Analysts maintain a "Moderate …

Pfizer Inc. $PFE Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP significantly reduced its stake in Pfizer Inc. by 37.7% in the second quarter of 2026, selling over 510,000 shares. Despite this, Pfizer reported strong Q2 earnings, exceeding analyst expectations for both EPS and revenue, and raised the low end of …

Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead

Gilead Sciences, Inc. has reported a beneficial ownership of 24.7% in Arcus Biosciences, Inc. (NYSE: RCUS), holding 31,424,760 shares out of 127,333,376 outstanding. This stake was built through multiple equity purchases dating back to 2020 and is linked to an Option, License and Collaboration …

Organon & Co stock hits 52-week high at 13.61 USD

Organon & Co (OGN) stock has reached a new 52-week high of $13.61, marking a 47.51% increase over the past year and reflecting strong investor confidence. The company also announced several recent developments, including a global licensing agreement for Miudella, exclusive commercialization rights for …

EU Approves Sanofi's MenQuadfi for Infants as Young as 6 Weeks, Expanding Protection Against a Leading Cause of Acquired Deafness

The European Commission has approved Sanofi's MenQuadfi vaccine for use in infants as young as 6 weeks, expanding protection against invasive meningococcal disease. This decision is significant for hearing healthcare professionals, as the disease is a leading cause of acquired sensorineural hearing loss in …

Merck (MRK) tech chief exercises 52,847 stock options, sells all shares

David Michael Williams, EVP and Chief Information & Digital Officer at Merck & Co., Inc. (MRK), exercised 52,847 stock options on August 5, 2026, at various strike prices. He subsequently sold all 52,847 shares at a weighted average price of $128.7707, generating approximately $2.87 …

Merck & Co., Inc. 2026: Revenue $16.61B, EPS ($0.54) — 10-Q Summary

Merck & Co., Inc. reported Q2 2026 results with revenue of $16.61 billion, a 5.1% increase year-over-year, but net income swung to a loss of ($1.34 billion) and diluted EPS was ($0.54). Revenue growth was driven by oncology, cardiometabolic/respiratory products, and animal health, with …

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as Official Action Indicated (OAI) Scholar Rock continuing to collaborate closely with FDA and …

AbbVie (ABBV) Is Down 5.3% After Raising 2026 Revenue Outlook and Issuing New Debt - What's Changed

In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie …

Scilex Holding Company Revenue Breakdown – BOATS:SCLXW

This article provides a revenue breakdown for Scilex Holding Company (SCLXW). It highlights that the United States was the primary contributor to its revenue, accounting for $30.25 million last year and $56.59 million the year before. The data is presented from a financial overview …

Merck (NYSE: MRK) EVP Guindo Chirfi sells 15,000 company shares

Merck & Co., Inc. EVP Guindo Chirfi sold 15,000 shares of common stock on August 6, 2026, at a price of $131.00 per share. This transaction, classified as an open-market or private sale, resulted in Chirfi directly owning 46,613 shares of Merck common stock …

Novo Nordisk Stock Rises After GLP-1 Antitrust Win

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, …

Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound

Key Points Pfizer's berobenatide appears to be a promising candidate that could challenge Wegovy and Zepbound. There are several other reasons to consider the stock, despite the potential headwinds ahead. 10 stocks we like better than Pfizer › The past few years have been …

Is Biogen (BIIB) Fully Priced After Earnings Raised Revenue But Cut Profit?

Biogen (BIIB) recently reported Q2 2026 earnings with higher sales but lower net income, raising questions about its current valuation. Despite a 61.47% shareholder return over the past year, the stock is considered 9.4% undervalued by analysts based on long-term growth for its Alzheimer's …

Roche Stock Jumps as Morgan Stanley Sees Drug Breakout

This article first appeared on GuruFocus. Roche Holding (RHHBY), the Swiss pharmaceutical and diagnostics giant, got a major Wall Street vote of confidence after Morgan Stanley upgraded the stock to Overweight from Equal Weight and hiked its ADR price target to $63 from $46. …

Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of …

Catalyst Watch: Inflation reads, AMAT earnings, Google Pixel event, and MLB on Netflix

[Lower Manhattan Cityscape] Art Wager/E+ via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. MONDAY - AUGUST 10 * …